Methodist Women's Hospital
Omaha, Nebraska, 68022, United States
Location status: Recruiting
Location contact
Joshua Dahlke, MD
CONTACT
Todd Lovgren
CONTACT
Todd Lovgren, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07023003
This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine.
Investigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study.
The only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.
Interested in participating?
Request Info19 year and older
Female
Interventional
Phase 4
Omaha, Nebraska, 68022, United States
Location status: Recruiting
Joshua Dahlke, MD
CONTACT
Todd Lovgren
CONTACT
Todd Lovgren, MD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Enalapril 10mg PO QD will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.
Other names: vasotec, enalaprilat, epaned
Nifedipine 30mg XL BID will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.
Other names: adalat, procardia
Time frame: Within 6 weeks of delivery
Number of participants meeting criteria for hospital admission.
Contact information is provided by the study sponsor or research team.
Joshua Dahlke, MD
CONTACT
Todd Lovgren, MD
CONTACT
Nebraska Methodist Health System
Other
Postpartum Evaluation of Antihypertensives for Control of Hypertension: A Randomized Controlled Equivalence Study
Acronym: PEACE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06835959
Cardiovascular Diseases, Chronic Hypertension
Worcester, Massachusetts, United States
View Trial DetailsNCT06466161
Body Weight, Cardiovascular Diseases
Chicago, Illinois, United States
View Trial DetailsNCT07356518
Cardiovascular Diseases, Female Urogenital Diseases and Pregnancy Complications
Winston-Salem, North Carolina, United States
View Trial DetailsNCT06105775
Cardiovascular Diseases, Female Urogenital Diseases and Pregnancy Complications
Ribeirão Preto, São Paulo, Brazil
View Trial Details